CN115697416A - 核酸配体偶联物及其用于向细胞递送的用途 - Google Patents

核酸配体偶联物及其用于向细胞递送的用途 Download PDF

Info

Publication number
CN115697416A
CN115697416A CN202180037230.3A CN202180037230A CN115697416A CN 115697416 A CN115697416 A CN 115697416A CN 202180037230 A CN202180037230 A CN 202180037230A CN 115697416 A CN115697416 A CN 115697416A
Authority
CN
China
Prior art keywords
nucleic acid
coupling product
linker
polypeptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037230.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·佩科特
S·H·阿扎姆
A·鲍尔斯
M·C·费莱明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Priority to CN202610037779.7A priority Critical patent/CN121775155A/zh
Publication of CN115697416A publication Critical patent/CN115697416A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180037230.3A 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途 Pending CN115697416A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610037779.7A CN121775155A (zh) 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024142P 2020-05-13 2020-05-13
US63/024,142 2020-05-13
PCT/US2021/031903 WO2021231518A1 (en) 2020-05-13 2021-05-12 Nucleic acid ligand conjugates and use thereof for delivery to cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610037779.7A Division CN121775155A (zh) 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途

Publications (1)

Publication Number Publication Date
CN115697416A true CN115697416A (zh) 2023-02-03

Family

ID=78524924

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180037230.3A Pending CN115697416A (zh) 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途
CN202610037779.7A Pending CN121775155A (zh) 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610037779.7A Pending CN121775155A (zh) 2020-05-13 2021-05-12 核酸配体偶联物及其用于向细胞递送的用途

Country Status (6)

Country Link
US (1) US20230285579A1 (https=)
EP (1) EP4149557A4 (https=)
JP (1) JP2023526277A (https=)
CN (2) CN115697416A (https=)
CA (1) CA3174467A1 (https=)
WO (1) WO2021231518A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117865868A (zh) * 2023-05-19 2024-04-12 湖南大学 一种功能化分子、其制备方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102864A2 (en) * 2022-11-08 2024-05-16 Purdue Research Foundation Multivalent multispecific conjugates and related compositions and methods of use
EP4687988A2 (en) * 2023-03-28 2026-02-11 KIST (Korea Institute of Science and Technology) Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
CN102317303A (zh) * 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO2009002440A2 (en) * 2007-06-22 2008-12-31 Intradigm Corporation Compositions comprising human egfr-sirna and methods of use
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
CN105722851A (zh) * 2013-04-28 2016-06-29 秦刚 一种新型的连接子及其制备方法和用途
WO2017127473A1 (en) * 2016-01-19 2017-07-27 The University Of North Carolina At Chapel Hill Methods and compositions using rna interference for inhibition of kras
CN109641038A (zh) * 2016-07-01 2019-04-16 小利兰·斯坦福大学理事会 靶向细胞表面编辑的共轭物
SG11201906728TA (en) * 2017-02-06 2019-08-27 Mpeg La Llc Multimeric oligonucleotides having decreased kidney clearance
US20200002746A1 (en) * 2017-02-14 2020-01-02 Seqwell, Inc. Compositions and methods for sequencing nucleic acids
KR102353086B1 (ko) * 2018-09-07 2022-01-20 아주대학교산학협력단 신규 면역독소 제조방법
JP7839554B2 (ja) * 2020-04-07 2026-04-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
CN102317303A (zh) * 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INES TRUEBENBACH ET AL.: "Co-delivery of pretubulysin and siEG5 to EGFR overexpressing carcinoma cells", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 26 July 2019 (2019-07-26), pages 8 - 9 *
KOLDO URBIOLA ET AL.: "Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to th e Transferrin and Epidermal Growth Factor Receptors", J PERS MED., 9 January 2018 (2018-01-09) *
孙立春 等: "受体靶向多肽载体抗肿瘤药物", 上海医药, 10 January 2015 (2015-01-10) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117865868A (zh) * 2023-05-19 2024-04-12 湖南大学 一种功能化分子、其制备方法及其应用
CN117865868B (zh) * 2023-05-19 2024-09-06 湖南大学 一种功能化分子、其制备方法及其应用

Also Published As

Publication number Publication date
EP4149557A1 (en) 2023-03-22
WO2021231518A1 (en) 2021-11-18
CA3174467A1 (en) 2021-11-18
CN121775155A (zh) 2026-04-03
EP4149557A4 (en) 2025-01-15
US20230285579A1 (en) 2023-09-14
JP2023526277A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
CN107921147B (zh) 一种新的前体miRNA及其在肿瘤治疗中的应用
US20230056466A1 (en) Novel precursor mirna and application thereof in tumor treatment
Singh et al. RNA interference nanotherapeutics for treatment of glioblastoma multiforme
JP2011516094A (ja) 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
US20210244826A1 (en) Short interfering rna templated lipoprotein particles (sirna-tlp)
CN115697416A (zh) 核酸配体偶联物及其用于向细胞递送的用途
EP2296669B1 (en) Targeted oligonucleotide compositions for modifying gene expression
US11618901B2 (en) Anti-miRNA carrier conjugated with a peptide binding to a cancer cell surface protein and use thereof
US20240167022A1 (en) Template directed immunomodulation for cancer therapy
US9872925B2 (en) Vitamin B6-coupled poly(ester amine) as gene carrier and application in cancer gene therapy
Chen et al. Aminoguanidine-assembled functional DNA tetrahedron alleviates acute lung injury by targeting the cGAS-STING signaling pathway
WO2021234647A1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
US20240309384A1 (en) INVERTED CHIMERIC siRNA MOLECULES AND METHODS OF USE THEREOF
CN114245747A (zh) 医疗用途、方法和用途
JP7839554B2 (ja) Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物
KR102104478B1 (ko) miR-133a-3p를 유효성분으로 함유하는 항암제 민감성 증진용 조성물
CN101821410B (zh) 印迹位点调节物兄弟(boris)的基因沉默
US20250376679A1 (en) Methods and compositions for inhibition of irf4
JP2010529852A (ja) 癌治療のためのＮｕＭＡのＲＮＡｉ媒介ノックダウン
Manesh et al. The targeted delivery of anti-metastasis oligonucleotide in breast cancer cells by the nanoliposomes conjugated with RGD ligand
Class et al. Patent application title: SHORT INTERFERING RNA TEMPLATED LIPOPROTEIN PARTICLES (SIRNA-TLP)
WO2024263883A2 (en) 5' antisense dna modifications to enhance rna interference activity
WO2023118294A1 (en) Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination